Literature DB >> 27136934

Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

Valentina Crudo1, Silvia Monticone1, Jacopo Burrello1, Fabrizio Buffolo1, Martina Tetti1, Franco Veglio1, Paolo Mulatero2.   

Abstract

Primary aldosteronism (PA), characterized by the inappropriate and abnormal adrenal secretion of aldosterone, is the most common cause of secondary hypertension. PA has been shown to increase cardiovasular and cerebrovascular risks in comparison with essential hypertension. PA is a multi-faceted disease, which comprises unilateral forms, benefitting from surgical treatment, and bilateral forms, which are the best managed medically. PA is more frequently sporadic, but in some cases, it displays a familial transmission pattern. For these reasons, it is important to diagnose PA early on and correctly distinguish and manage its different forms. In this review, we analyze the different forms of PA, with attention on the diagnostic pathway and the genetics of the disease.

Entities:  

Keywords:  Adrenal vein sampling; Aldosterone producing adenoma; Primary aldosteronism; Secondary hypertension

Mesh:

Substances:

Year:  2016        PMID: 27136934     DOI: 10.1007/s40292-016-0151-6

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  51 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism.

Authors:  Gian Paolo Rossi; Marlena Barisa; Bruno Allolio; Richard J Auchus; Laurence Amar; Debbie Cohen; Christoph Degenhart; Jaap Deinum; Evelyn Fischer; Richard Gordon; Ralph Kickuth; Gregory Kline; Andre Lacroix; Steven Magill; Diego Miotto; Mitsuhide Naruse; Tetsuo Nishikawa; Masao Omura; Eduardo Pimenta; Pierre-François Plouin; Marcus Quinkler; Martin Reincke; Ermanno Rossi; Lars Christian Rump; Fumitoshi Satoh; Leo Schultze Kool; Teresa Maria Seccia; Michael Stowasser; Akiyo Tanabe; Scott Trerotola; Oliver Vonend; Jiri Widimsky; Kwan-Dun Wu; Vin-Cent Wu; Achille Cesare Pessina
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

3.  Mass Spectrometry-Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism.

Authors:  Graeme Eisenhofer; Tanja Dekkers; Mirko Peitzsch; Anna S Dietz; Martin Bidlingmaier; Marcus Treitl; Tracy A Williams; Stefan R Bornstein; Matthias Haase; L C Rump; Holger S Willenberg; Felix Beuschlein; Jaap Deinum; Jacques W M Lenders; Martin Reincke
Journal:  Clin Chem       Date:  2016-01-19       Impact factor: 8.327

Review 4.  Primary aldosteronism: who should be screened?

Authors:  S Monticone; A Viola; D Tizzani; V Crudo; J Burrello; M Galmozzi; F Veglio; P Mulatero
Journal:  Horm Metab Res       Date:  2011-11-25       Impact factor: 2.936

5.  Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms).

Authors:  Paolo Mulatero; Davide Tizzani; Andrea Viola; Chiara Bertello; Silvia Monticone; Giulio Mengozzi; Domenica Schiavone; Tracy Ann Williams; Silvia Einaudi; Antonio La Grotta; Franco Rabbia; Franco Veglio
Journal:  Hypertension       Date:  2011-08-29       Impact factor: 10.190

6.  Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism.

Authors:  Fumitoshi Satoh; Ryo Morimoto; Yoshikiyo Ono; Yoshitsugu Iwakura; Kei Omata; Masataka Kudo; Kei Takase; Kazumasa Seiji; Hidehiko Sasamoto; Seijiro Honma; Mitsunobu Okuyama; Kouwa Yamashita; Celso E Gomez-Sanchez; William E Rainey; Yoichi Arai; Hironobu Sasano; Yasuhiro Nakamura; Sadayoshi Ito
Journal:  Hypertension       Date:  2015-03-16       Impact factor: 10.190

7.  K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.

Authors:  Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

Review 8.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

9.  A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.

Authors:  R P Lifton; R G Dluhy; M Powers; G M Rich; S Cook; S Ulick; J M Lalouel
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

Review 10.  An Update on Familial Hyperaldosteronism.

Authors:  H E Korah; U I Scholl
Journal:  Horm Metab Res       Date:  2015-10-07       Impact factor: 2.936

View more
  3 in total

Review 1.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

Review 2.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

3.  Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy.

Authors:  Xiao Wang; Daniel A Heinrich; Sonja L Kunz; Nina Heger; Lisa Sturm; Olaf Uhl; Felix Beuschlein; Martin Reincke; Martin Bidlingmaier
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.